MX2021004540A - Inmunoterapia de combinación para el tratamiento de cáncer de mama triple-negativo. - Google Patents
Inmunoterapia de combinación para el tratamiento de cáncer de mama triple-negativo.Info
- Publication number
- MX2021004540A MX2021004540A MX2021004540A MX2021004540A MX2021004540A MX 2021004540 A MX2021004540 A MX 2021004540A MX 2021004540 A MX2021004540 A MX 2021004540A MX 2021004540 A MX2021004540 A MX 2021004540A MX 2021004540 A MX2021004540 A MX 2021004540A
- Authority
- MX
- Mexico
- Prior art keywords
- individual
- her2
- neu
- triple
- breast cancer
- Prior art date
Links
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 title abstract 6
- 208000022679 triple-negative breast carcinoma Diseases 0.000 title abstract 6
- 238000011220 combination immunotherapy Methods 0.000 title 1
- 101150029707 ERBB2 gene Proteins 0.000 abstract 4
- 229960000575 trastuzumab Drugs 0.000 abstract 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 2
- AHOKKYCUWBLDST-QYULHYBRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2,6-diaminohexanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=CC=C1 AHOKKYCUWBLDST-QYULHYBRSA-N 0.000 abstract 1
- 108010024405 HER2 peptide (369-377) Proteins 0.000 abstract 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 1
- 108010033276 Peptide Fragments Proteins 0.000 abstract 1
- 102000007079 Peptide Fragments Human genes 0.000 abstract 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 239000000568 immunological adjuvant Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000037452 priming Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/812—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a un método para tratar cáncer de mama triple-negativo (TNBC) en un individuo, y/o para inducir una respuesta inmune a Her2/neu en un individuo con cáncer de mama triple-negativo que expresa bajos niveles de HER2/neu, el método comprende administrar al individuo: (a) una cantidad efectiva de trastuzumab o derivado de la misma; y (b) una cantidad efectiva de nelipepimut-S, o variante de la misma, opcionalmente con un adyuvante inmunológico; preferiblemente, el método incluye una fase preparatoria o de imprimación que comprende una frecuencia y duración de la administración de trastuzumab o derivado de trastuzumab suficiente para incrementar sustancialmente la presentación mediada por el complejo principal de histocompatibilidad (MHC) de fragmentos de péptido HER2 al sistema inmunológico del paciente; la invención también incluye medicamentos y kits para tratar TNBC en un individuo, y/o para inducir una respuesta inmune a HER2/neu en un individuo con un TNBC que expresa HER2/neu.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862748511P | 2018-10-21 | 2018-10-21 | |
| US201962855650P | 2019-05-31 | 2019-05-31 | |
| PCT/US2019/057095 WO2020086412A1 (en) | 2018-10-21 | 2019-10-19 | Combination immunotherapy for treatment of triple-negative breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021004540A true MX2021004540A (es) | 2021-09-28 |
Family
ID=70279289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021004540A MX2021004540A (es) | 2018-10-21 | 2019-10-19 | Inmunoterapia de combinación para el tratamiento de cáncer de mama triple-negativo. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11564987B2 (es) |
| EP (1) | EP3866853A4 (es) |
| JP (1) | JP2022512038A (es) |
| KR (1) | KR20210104672A (es) |
| CN (1) | CN113543805A (es) |
| AU (1) | AU2019364258A1 (es) |
| CA (1) | CA3117145A1 (es) |
| IL (1) | IL282471A (es) |
| MA (1) | MA53933A (es) |
| MX (1) | MX2021004540A (es) |
| WO (1) | WO2020086412A1 (es) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| ATE273615T1 (de) | 1999-06-25 | 2004-09-15 | Lonza Ag | Desinfektionsmittel |
| AU2003230603A1 (en) | 2002-03-08 | 2003-09-22 | Board Of Regents, The University Of Texas System | Controlled modulation of amino acid side chain length of peptide antigens |
| US8945573B2 (en) * | 2005-09-08 | 2015-02-03 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Targeted identification of immunogenic peptides |
| SI2162149T1 (sl) | 2007-06-01 | 2014-04-30 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Cepivo za preprečevanje relapsa raka na dojki |
| US8569262B2 (en) * | 2007-11-02 | 2013-10-29 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| NZ602084A (en) * | 2010-03-11 | 2014-07-25 | Merrimack Pharmaceuticals Inc | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| GB201309807D0 (en) * | 2013-05-31 | 2013-07-17 | Pharma Mar Sau | Antibody drug conjugates |
| CA2987730C (en) * | 2015-04-08 | 2020-02-18 | Nantomics, Llc | Cancer neoepitopes |
| CN107614015A (zh) * | 2015-05-30 | 2018-01-19 | 豪夫迈·罗氏有限公司 | 治疗her2阳性局部晚期或先前未治疗的转移性乳腺癌的方法 |
| CA3021445A1 (en) * | 2016-04-19 | 2017-10-26 | Exelixis, Inc. | Triple negative breast cancer treatment method |
-
2019
- 2019-10-19 KR KR1020217015475A patent/KR20210104672A/ko not_active Application Discontinuation
- 2019-10-19 CA CA3117145A patent/CA3117145A1/en active Pending
- 2019-10-19 MA MA053933A patent/MA53933A/fr unknown
- 2019-10-19 MX MX2021004540A patent/MX2021004540A/es unknown
- 2019-10-19 EP EP19876203.1A patent/EP3866853A4/en active Pending
- 2019-10-19 JP JP2021547041A patent/JP2022512038A/ja active Pending
- 2019-10-19 US US16/658,047 patent/US11564987B2/en active Active
- 2019-10-19 CN CN201980084792.6A patent/CN113543805A/zh active Pending
- 2019-10-19 WO PCT/US2019/057095 patent/WO2020086412A1/en unknown
- 2019-10-19 AU AU2019364258A patent/AU2019364258A1/en not_active Abandoned
-
2021
- 2021-04-20 IL IL282471A patent/IL282471A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11564987B2 (en) | 2023-01-31 |
| JP2022512038A (ja) | 2022-02-01 |
| WO2020086412A1 (en) | 2020-04-30 |
| KR20210104672A (ko) | 2021-08-25 |
| CA3117145A1 (en) | 2020-04-30 |
| IL282471A (en) | 2021-06-30 |
| MA53933A (fr) | 2021-08-25 |
| EP3866853A4 (en) | 2022-08-03 |
| CN113543805A (zh) | 2021-10-22 |
| AU2019364258A1 (en) | 2021-06-03 |
| US20200121789A1 (en) | 2020-04-23 |
| EP3866853A1 (en) | 2021-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sims | Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer | |
| PH12017500484A1 (en) | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers | |
| MX2020008977A (es) | Formulaciones de anticuerpos de her2 subcutaneas. | |
| NZ734197A (en) | Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers | |
| SG10201807588TA (en) | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers | |
| MX2021001762A (es) | Metodo y composicion para estimular la respuesta inmunitaria. | |
| RU2747124C2 (ru) | Способы лечения метастатического рака поджелудочной железы с помощью комбинированной терапии, включающей применение иринотекана и оксалиплатина | |
| MX2020010144A (es) | Dosificación subcutánea de anticuerpos anti grupo de diferenciación 38 (cd38). | |
| RU2020120593A (ru) | Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом | |
| MX2018011388A (es) | Peptidos novedosos, combinacion de peptidos y soportes para usarse en el tratamiento inmunoterapeutico de varios tipos de cancer. | |
| WO2016011422A3 (en) | Manufacturing of multi-dose injection ready dendritic cell vaccines and combination therapy for blocking her2 and her3 | |
| JOP20210284A1 (ar) | الإعطاء غير المتجانس للقاحات تاو | |
| MX2020013601A (es) | Receptores de las celulas t especificos de cancer. | |
| MX2021004540A (es) | Inmunoterapia de combinación para el tratamiento de cáncer de mama triple-negativo. | |
| MX2021001288A (es) | Vacunacion con microvesiculas derivadas de celulas tumorales para tratamiento de cancer. | |
| EA201890148A1 (ru) | Способ индукции раннего ответа т-клеток памяти противоопухолевой вакциной из коротких пептидов | |
| MX2020011794A (es) | Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer. | |
| RU2021114203A (ru) | Комбинированная иммунотерапия для лечения трижды негативного рака молочной железы | |
| MX2019007906A (es) | Composicion vacunal que comprende un mutante de la interleucina-15 humana. | |
| STROMAL | 289 PGV-001: A PHASE 1 TRIAL OF A PERSONALIZED NEOANTIGEN PEPTIDE VACCINE FOR THE TREATMENT OF MALIGNANCIES IN THE ADJUVANT SETTING | |
| Draganov et al. | 290 Cytokine and immune subset signatures in patients with various solid and hematological malignancies treated with oncolytic vaccinia virus delivered by autologous stromal vascular fraction cells | |
| Helwick | Breast Cancer Vaccines Moving Forward at a Fast Clip | |
| MY195821A (en) | Novel Peptides and Combination of Peptides for use in Immunotherapy Against Hepatocellular Carcinoma (Hcc) and other Cancers | |
| 大竹淳矢 | Studies on effective induction of cancer antigen-specific T cells and its application for cancer immunotherapy [an abstract of entire text] | |
| Sheu | Papulopustular acneiform eruptions: 4 case reports |